Immix Biopharma, Inc. (IMMX) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
11400 West Olympic Boulevard
Los Angeles, CA 90064
United States of America (the)
Phone
310 651 8041
Website
Sector
Healthcare
Industry
Biotechnology
Employees
18
First IPO Date
December 16, 2021
| Name | Title | Pay | Year Born |
| Ilya Rachman | Co-Founder, CEO, Chief Scientific Officer & Chairman | 760,000 | 1973 |
| Graham Ross FFPM | Chief Medical Officer & Head of Clinical Development | 88,593 | 1960 |
| Gabriel Morris | President, CFO & Director | 760,000 | 1987 |
| Vladimir Torchilin | Scientific Co-Founder | 0 | 1947 |
| David Marks | Chief Medical Officer of Cell Therapy | 0 | N/A |
| Mel Davis-Pickett | Head of CMC Technical Development | 0 | N/A |
| Michael A. Grabow | Chief Commercial Officer | 0 | N/A |
| Sean Senn | Co-Founder | 0 | N/A |
Immix Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to creating a range of tissue-specific therapies. Operating in both the United States and Australia, their primary focus areas are oncology (cancer) and inflammatory diseases. Their product pipeline includes IMX-110, which is currently undergoing Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and various solid tumors. They are also developing IMX-111, a targeted biologic agent for colorectal cancers, and IMX-120, another tissue-specific biologic designed to address ulcerative colitis and severe Crohn's disease. In a strategic move, the company has forged a clinical collaboration and supply agreement with BeiGene Ltd. This partnership aims to conduct a Phase 1b combination clinical trial, evaluating IMX-110 in conjunction with BeiGene's anti-PD-1 drug, Tislelizumab, for solid tumor indications. Founded in 2012, Immix Biopharma maintains its headquarters in Los Angeles, California.